$GRST
ETHEMA HEALTH Corp Stock $grst

$grst Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000190359623000455 Filed on May 22, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.566M	$1.300M	$1.023M
YoY Change	37.6%	27.04%	1027.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.394M	$1.087M	$816.4K
YoY Change	46.45%	33.09%	4004.47%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$139.6K	$138.5K	$132.0K
YoY Change	3.99%	4.91%	310.83%
% of Gross Profit
Operating Expenses	$1.534M	$1.225M	$948.4K
YoY Change	41.2%	29.17%	1723.11%
Operating Profit	$32.15K	$75.03K	$74.94K
YoY Change	-37.9%	0.11%
Interest Expense	-$319.3K	$47.73K	-$231.7K
YoY Change	53.72%	-120.6%	-82.59%
% of Operating Profit	-993.28%	63.62%	-309.15%
Other Income/Expense, Net	$339.00		$10.02K
YoY Change	-67.56%
Pretax Income	-$451.5K	-$162.0K	-$146.7K
YoY Change	191.45%	10.38%	-93.8%
Income Tax	-$219.4K	-$13.77K	$18.26K
% Of Pretax Income
Net Earnings	-$232.2K	-$175.7K	-$174.5K
YoY Change	19.8%	0.73%	-92.63%
Net Earnings / Revenue	-14.83%	-13.52%	-17.05%
Basic Earnings Per Share	$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$48.05
COMMON SHARES
Basic Shares Outstanding	3.729B shares	3.729B shares
Diluted Shares Outstanding	3.729B shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.81K	$27.58K	$27.02K
YoY Change	-59.78%	2.07%	-97.46%
Cash & Equivalents	$27.81K	$27.58K	$27.02K
Short-Term Investments
Other Short-Term Assets	$55.30K	$84.82K	$37.69K
YoY Change	193.84%	125.05%	-72.39%
Inventory
Prepaid Expenses	$26.00K	$34.14K
Receivables	$470.8K	$543.1K	$291.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$579.9K	$689.7K	$355.7K
YoY Change	22.1%	93.88%	-70.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$531.3K	$2.980M	$4.674M
YoY Change	-82.84%	-36.24%	61.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$450.0K	$5.190K
YoY Change	7852.29%	8570.52%	0.58%
Total Long-Term Assets	$3.256M	$5.916M	$6.200M
YoY Change	-46.26%	-4.58%	114.47%
TOTAL ASSETS
Total Short-Term Assets	$579.9K	$689.7K	$355.7K
Total Long-Term Assets	$3.256M	$5.916M	$6.200M
Total Assets	$3.836M	$6.606M	$6.556M
YoY Change	-41.29%	0.76%	60.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$131.2K	$372.8K	$360.3K
YoY Change	-65.54%	3.47%	-54.9%
Accrued Expenses	$311.3K	$299.0K	$252.3K
YoY Change	17.99%	18.5%
Deferred Revenue
YoY Change
Short-Term Debt	$793.7K	$496.9K	$7.874M
YoY Change	145.32%	-93.69%	4.81%
Long-Term Debt Due	$23.08K	$3.948M	$4.055M
YoY Change	-99.41%	-2.65%	1372.9%
Total Short-Term Liabilities	$9.857M	$14.07M	$13.67M
YoY Change	-29.71%	2.92%	-1.47%
LONG-TERM LIABILITIES
Long-Term Debt	$637.2K	$642.7K	$667.5K
YoY Change	-3.25%	-3.71%	-85.63%
Other Long-Term Liabilities	$1.042M	$1.971M	$1.425M
YoY Change	-23.01%	38.29%
Total Long-Term Liabilities	$1.865M	$1.971M	$2.093M
YoY Change	-16.99%	-5.83%	-54.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.857M	$14.07M	$13.67M
Total Long-Term Liabilities	$1.865M	$1.971M	$2.093M
Total Liabilities	$11.72M	$16.04M	$16.85M
YoY Change	-27.96%	-4.81%	-12.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.04M	-$43.69M
YoY Change	-1.09%
Common Stock	$37.29M	$37.29M
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.887M	-$9.433M	-$10.29M
YoY Change
Total Liabilities & Shareholders Equity	$3.836M	$6.606M	$6.556M
YoY Change	-41.29%	0.76%	60.19%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$232.2K	-$175.7K	-$174.5K
YoY Change	19.8%	0.73%	-92.63%
Depreciation, Depletion And Amortization	$139.6K	$138.5K	$132.0K
YoY Change	3.99%	4.91%	310.83%
Cash From Operating Activities	-$70.38K	$105.9K	-$69.07K
YoY Change	-122.27%	-253.29%	-10.95%
INVESTING ACTIVITIES
Capital Expenditures	-$30.78K	$52.42K	-$72.86K
YoY Change	-78.15%	-171.95%
Acquisitions
YoY Change
Other Investing Activities		-$50.00K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$80.78K	-$102.4K	-$72.86K
YoY Change	-157.34%	40.57%	-78.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-92.52K	-$117.7K	46.85K
YoY Change	-215.06%	-351.32%	-83.22%
NET CHANGE
Cash From Operating Activities	-70.38K	$105.9K	-69.07K
Cash From Investing Activities	80.78K	-$102.4K	-72.86K
Cash From Financing Activities	-92.52K	-$117.7K	46.85K
Net Change In Cash	-82.12K	-$113.2K	-95.08K
YoY Change	-132.13%	19.03%	-29.36%
FREE CASH FLOW
Cash From Operating Activities	-$70.38K	$105.9K	-$69.07K
Capital Expenditures	-$30.78K	$52.42K	-$72.86K
Free Cash Flow	-$39.60K	$53.45K	$3.790K
YoY Change	-108.67%	1310.4%	-104.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000792935
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2023Q1	grst	Derivative Liability Movements DerivativeLiabilityMovements		usd
CY2022Q1	us-gaap	Payments For Deposits PaymentsForDeposits		usd
CY2022Q1	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable		usd
CY2022Q1	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization		usd
CY2023Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable		usd
CY2022Q1	grst	Repayment Of Government Assistance Loans RepaymentOfGovernmentAssistanceLoans		usd
CY2023Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt		usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022Q1	grst	Repayment Of Related Party Notes RepaymentOfRelatedPartyNotes		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	grst	Conversion Of Convertible Notes ConversionOfConvertibleNotes		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2023Q1	grst	Segment Tax SegmentTax		usd
CY2023Q1	grst	Intercompany Balances IntercompanyBalances		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-54748
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ETHEMA HEALTH CORPORATION.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1227328
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	950 Evernia Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	West Palm Beach
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33401
CY2023Q1	dei	City Area Code CityAreaCode	(416)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	500-0020
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Security12b Title Security12bTitle	Common shares
CY2023Q1	dei	Trading Symbol TradingSymbol	GRST
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3729053805	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27580	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140757	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	543119	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	337074	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	34142	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	44718	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	84823	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	20347	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	689664	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	542896	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2979853	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2974395	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1163437	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1252932	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1322851	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1393071	usd
CY2023Q1	us-gaap	Deposit Contracts Assets DepositContractsAssets	450000	usd
CY2022Q4	us-gaap	Deposit Contracts Assets DepositContractsAssets	400000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	5916141	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6020398	usd
CY2023Q1	us-gaap	Assets Assets	6605805	usd
CY2022Q4	us-gaap	Assets Assets	6563294	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	372830	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	170934	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	282878	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	248644	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5351270	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5269250	usd
CY2023Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	496923	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	460534	usd
CY2023Q1	us-gaap	Secured Debt SecuredDebt	3478130	usd
CY2022Q4	us-gaap	Secured Debt SecuredDebt	3504605	usd
CY2023Q1	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	443459	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	416731	usd
CY2023Q1	us-gaap	Loans From Other Federal Home Loan Banks LoansFromOtherFederalHomeLoanBanks	61473	usd
CY2022Q4	us-gaap	Loans From Other Federal Home Loan Banks LoansFromOtherFederalHomeLoanBanks	14818	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	299027	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	287017	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8017	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7891	usd
CY2023Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	218357	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	194829	usd
CY2023Q1	grst	Related Party Payables RelatedPartyPayables	2655976	usd
CY2022Q4	grst	Related Party Payables RelatedPartyPayables	2713878	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14068340	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13289131	usd
CY2023Q1	grst	Government Assistance Loans Non Current GovernmentAssistanceLoansNonCurrent	29484	usd
CY2022Q4	grst	Government Assistance Loans Non Current GovernmentAssistanceLoansNonCurrent	79555	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	201919	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	217451	usd
CY2023Q1	grst	Third Party Loans ThirdPartyLoans	590372	usd
CY2022Q4	grst	Third Party Loans ThirdPartyLoans	578335	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1125990	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1206413	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22883	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24952	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1970648	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2106706	usd
CY2023Q1	us-gaap	Liabilities Liabilities	16038988	usd
CY2022Q4	us-gaap	Liabilities Liabilities	15395837	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3729053805	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	37290539	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	37290539	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23419917	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23419917	usd
CY2023Q1	us-gaap	Common Stock Discount On Shares CommonStockDiscountOnShares	27363367	usd
CY2022Q4	us-gaap	Common Stock Discount On Shares CommonStockDiscountOnShares	27363367	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6569	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5065	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43686855	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43484751	usd
CY2023Q1	grst	Stockholders Deficit Attributable To Ethema Health Corporation Stockholders StockholdersDeficitAttributableToEthemaHealthCorporationStockholders	-10306335	usd
CY2022Q4	grst	Stockholders Deficit Attributable To Ethema Health Corporation Stockholders StockholdersDeficitAttributableToEthemaHealthCorporationStockholders	-10102727	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	873152	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	870184	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-9433183	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9232543	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6605805	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6563294	usd
CY2023Q1	us-gaap	Revenues Revenues	1300046	usd
CY2022Q1	us-gaap	Revenues Revenues	1023315	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	241237	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	209932	usd
CY2023Q1	grst	Rent Expense RentExpense	114564	usd
CY2022Q1	grst	Rent Expense RentExpense	90031	usd
CY2023Q1	us-gaap	Management Fee Expense ManagementFeeExpense	27500	usd
CY2022Q1	us-gaap	Management Fee Expense ManagementFeeExpense	30000	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	111204	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	49587	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	592036	usd
CY2022Q1	us-gaap	Salaries And Wages SalariesAndWages	436825	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	138479	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	132000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1225020	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	948375	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	75026	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	74940	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10018	usd
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	157096	usd
CY2022Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	80768	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-76921	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-252832	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-197476	usd
CY2023Q1	grst	Foreign Exchange Movements ForeignExchangeMovements	-2955	usd
CY2022Q1	grst	Foreign Exchange Movements ForeignExchangeMovements	-95556	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-161946	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-146722	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13771	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18263	usd
CY2023Q1	grst	Consolidated Net Loss ConsolidatedNetLoss	-175717	usd
CY2022Q1	grst	Consolidated Net Loss ConsolidatedNetLoss	-164985	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2968	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9462	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-178685	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-174447	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	23419	usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24613	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-202104	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-199060	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Cost Foreign Currency Translation Adjustment And Other DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther	1504	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Cost Foreign Currency Translation Adjustment And Other DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther	-34517	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-203608	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-164543	usd
CY2023Q1	grst	Basic And Diluted Loss Per Common Share BasicAndDilutedLossPerCommonShare	-0.00
CY2022Q1	grst	Basic And Diluted Loss Per Common Share BasicAndDilutedLossPerCommonShare	-0.00
CY2023Q1	grst	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	3729053805	shares
CY2022Q1	grst	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	3630720472	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9232543	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-1504	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-175717	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	23419	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-9433183	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9855381	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	150000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	34517	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-164985	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	24613	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9860462	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-175717	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-164985	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138479	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	132000	usd
CY2023Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	76921	usd
CY2022Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	252832	usd
CY2022Q1	grst	Derivative Liability Movements DerivativeLiabilityMovements	-197476	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	70219	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	63064	usd
CY2023Q1	grst	Deferred Taxation Movement DeferredTaxationMovement	-15532	usd
CY2022Q1	grst	Deferred Taxation Movement DeferredTaxationMovement	-18794	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	151744	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	115000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	10576	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	10456	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-64476	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1171	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	251384	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-22013	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-68413	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-57156	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	34177	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	49169	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	105874	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69074	usd
CY2023Q1	us-gaap	Payments For Deposits PaymentsForDeposits	50000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	52418	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	72858	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102418	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72858	usd
CY2023Q1	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	29300	usd
CY2022Q1	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	29850	usd
CY2023Q1	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	190000	usd
CY2023Q1	us-gaap	Repayments Of Accounts Receivable Securitization RepaymentsOfAccountsReceivableSecuritization	204133	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	10000	usd
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	201733	usd
CY2022Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	100000	usd
CY2023Q1	grst	Repayment Of Government Assistance Loans RepaymentOfGovernmentAssistanceLoans	-3449	usd
CY2022Q1	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	78977	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1944	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1822	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	259228	usd
CY2023Q1	grst	Repayment Of Related Party Notes RepaymentOfRelatedPartyNotes	-58917	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-117743	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46846	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1110	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73288	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-113177	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21798	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140757	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48822	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27580	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27024	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	53310	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	43304	usd
CY2022Q1	grst	Conversion Of Convertible Notes ConversionOfConvertibleNotes	150000	usd
CY2023Q1	grst	Finite Lived Intangible Asset Useful Life One FiniteLivedIntangibleAssetUsefulLifeOne	5 years
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1789903	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	626466	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1163437	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1252932	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	89495	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	89495	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_z0wabegGciib" style="margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span style="background-color: white"><span id="xdx_824_zEyLgf3U4xtc">Nature of business</span></span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Since 2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings and operated an addiction treatment center in Delray Beach Florida under its Addiction Recovery Institute of America subsidiary with a license obtained in December 2016, initially through owned properties in Delray Beach and subsequently though leased properties in West Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by Evernia in West Palm Beach, Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia, once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is the only active treatment center operated by the Company.</span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0 0 0 0.25in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company also owns the real estate on which its Greenstone Muskoka clinic operated. The current tenant operates an addiction treatment center on these premises. The Company collects rent on this property, which is treated as a separate business segment.<b> </b></span></p> <p style="margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> <b> </b></span></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zFBaCPmj256b" style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>a) <span id="xdx_864_zAbSom8XZTEc">Use of Estimates</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="margin: 0 0 0 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	250000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	35281	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	38079	usd
CY2023Q1	grst	Rightofuse Assets Operating Leases Net Of Amortization RightofuseAssetsOperatingLeasesNetOfAmortization	1322851	usd
CY2022Q4	grst	Rightofuse Assets Operating Leases Net Of Amortization RightofuseAssetsOperatingLeasesNetOfAmortization	1393071	usd
CY2023Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	543119	usd
CY2022Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	337074	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3807578	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	827725	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2979853	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2974395	usd
CY2023Q1	us-gaap	Depreciation Depreciation	48494	usd
CY2022Q1	us-gaap	Depreciation Depreciation	42505	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2797	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2797	usd
CY2023Q1	grst	Interest Expense On Finance Lease Liabilities InterestExpenseOnFinanceLeaseLiabilities	526	usd
CY2022Q1	grst	Interest Expense On Finance Lease Liabilities InterestExpenseOnFinanceLeaseLiabilities	648	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3323	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	3445	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	86127	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	63064	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	89450	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	186727	usd
CY2023Q1	grst	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-526	usd
CY2022Q1	grst	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-648	usd
CY2023Q1	grst	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-86127	usd
CY2022Q1	grst	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-63064	usd
CY2023Q1	grst	Financing Cash Flows From Finance Leases FinancingCashFlowsFromFinanceLeases	-1944	usd
CY2022Q1	grst	Financing Cash Flows From Finance Leases FinancingCashFlowsFromFinanceLeases	-1809	usd
CY2023Q1	grst	Net Change In Leases NetChangeInLeases	-88597	usd
CY2022Q1	grst	Net Change In Leases NetChangeInLeases	-65521	usd
CY2023Q1	grst	Weighted Average Lease Term Finance Leases Term WeightedAverageLeaseTermFinanceLeasesTerm	3 years and seven months
CY2022Q1	grst	Weighted Average Lease Term Finance Leases Term WeightedAverageLeaseTermFinanceLeasesTerm	4 years and seven months
CY2023Q1	grst	Weighted Average Remaining Lease Term Operating Leases WeightedAverageRemainingLeaseTermOperatingLeases	3 years and 10 months
CY2022Q1	grst	Weighted Average Remaining Lease Term Operating Leases WeightedAverageRemainingLeaseTermOperatingLeases	4 years and 10 months
CY2023Q1	grst	Discount Rate Finance Leases DiscountRateFinanceLeases	0.0660	pure
CY2022Q1	grst	Discount Rate Finance Leases DiscountRateFinanceLeases	0.0661	pure
CY2023Q1	grst	Discount Rate Operating Leases DiscountRateOperatingLeases	0.0464	pure
CY2022Q1	grst	Discount Rate Operating Leases DiscountRateOperatingLeases	0.0464	pure
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	7372	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	9829	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	9829	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	6195	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	1707	usd
CY2023Q1	grst	Total Undiscounted Minimum Future Lease Payment TotalUndiscountedMinimumFutureLeasePayment	34932	usd
CY2023Q1	grst	Imputed Interest ImputedInterest	-4032	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	30900	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	8017	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22883	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	30900	usd
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	262549	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	366110	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	384416	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	403637	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	33771	usd
CY2023Q1	grst	Total Undiscounted Minimum Future Lease Payments TotalUndiscountedMinimumFutureLeasePayments	1450483	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	25465	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1425017	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	299027	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1125990	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1425017	usd
CY2023Q1	grst	Derived Rental Income DerivedRentalIncome	89419	usd
CY2023Q1	grst	Debt Instrument Of Principal Amount DebtInstrumentOfPrincipalAmount	4378754	usd
CY2023Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	972516	usd
CY2023Q1	grst	Shortterm Convertible ShorttermConvertible	5351270	usd
CY2022	grst	Shortterm Convertible ShorttermConvertible	5269250	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.042	pure
CY2023Q1	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	3473334	usd
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	4796	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	623777506	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0052875
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20925000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.12
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	602852506	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.001306
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	602852506	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.001306
CY2023Q1	grst	Warrants Outstanding WarrantsOutstanding	602852506	shares
CY2023Q1	grst	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceTerm	P2Y6M3D
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001306
CY2023Q1	grst	Warrants Exercisable WarrantsExercisable	602852506	shares
CY2023Q1	grst	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable	0.001306
CY2023Q1	grst	Revenues1 Revenues1	89419	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	30120	usd
CY2023Q1	grst	Operating Income Loss1 OperatingIncomeLoss1	59299	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	47733	usd
CY2023Q1	grst	Foreign Exchange Movements One ForeignExchangeMovementsOne	-1035	usd
CY2023Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	10531	usd
CY2023Q1	grst	Net Income Loss One NetIncomeLossOne	10531	usd
CY2023Q1	grst	Purchase Of Fixed Assets1 PurchaseOfFixedAssets1	52418	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	689664	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	5916141	usd
CY2023Q1	grst	Operating Assets And Liabilities OperatingAssetsAndLiabilities	-14068340	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1970648	usd
CY2023Q1	grst	Net Liability Assetposition NetLiabilityAssetposition	-9433183	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1185143076	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1069575454	shares

Files In Submission

Name	View Source	Status
grst-20230331_def.xml	Edgar Link	unprocessable
grst-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001903596-23-000455-index-headers.html	Edgar Link	pending
0001903596-23-000455-index.html	Edgar Link	pending
0001903596-23-000455.txt	Edgar Link	pending
0001903596-23-000455-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
grst-20230331.xsd	Edgar Link	pending
grst_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
grst-20230331_pre.xml	Edgar Link	unprocessable
grst-20230331_lab.xml	Edgar Link	unprocessable
grst_10q_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GRST
ETHEMA HEALTH Corp Stock $grst

2023 Q2 Form 10-Q Financial Statement

#000190359623000455 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRST ETHEMA HEALTH Corp Stock $grst

2023 Q2 Form 10-Q Financial Statement

#000190359623000455 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GRST
ETHEMA HEALTH Corp Stock $grst